Drug Discovery news from FierceBiotech
News
Study projects new wave of globalization in biopharma
Don't be misguided by dated reports discounting the impact Indian and Chinese scientists are having in drug development and other key technologies, says a new study from Duke and Harvard. Looking at Read more...
GSK outlines plans to become more ‘biotech-like’
Biotech is in. At least, that's the message from GlaxoSmithKline's Patrick Vallance, the pharma giant's head Read more...
GSK collaborates on immune disease research
GlaxoSmithKline has inked a five year, $25 million collaboration deal with the Disease Institute of Boston to conduct on immunoinflammation research. GSK and IDI researchers will develop joint grant Read more...
Syndexa gets $15M for metabolic disease work
With help from technology entrepreneur Dr. Yalcin Ayasli, Cambridge, MA-based Syndexa Pharmaceuticals has garnered $15 million in a second round of financing. The company previously raised about $4 Read more...
Takeda gains RNAi tech with $1B Alnylam deal
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal Read more...
Novartis restructures its development strategy
Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too Read more...
Biotech entrepreneurs grow a new CRO in China
Biotech entrepreneur John Oyler--who helped found Genta and Galanea--sat down with Chemistry World to discuss his three-year-old Read more...
SPOTLIGHT: Array lands $80M financing deal
Deerfield Management will provide $80 million to Array BioPharma to fund its drug discovery work. Array is advancing new therapies for inflammatory diseases and cancer. Principal and interest of 6.5 Read more...
Booming Chinese market lures Unigene joint venture
Unigene is racing to complete construction of new facilities in China that will house its joint venture with a Chinese pharma company. The joint venture plans to pursue R&D work as well as drug Read more...
ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc
> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88. Read more...
Get more Drug Discovery coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets